Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients

Justine Davies*, A. Gavin, M. Band, A. Morris, A. Struthers

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: To assess whether spironolactone has beneficial effects on blood pressure (BP), N-terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics. Methods: Ten patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months' treatment with spironolactone and placebo with a 4-week washout phase. BP, PIIINP and carotid-radial PWV were measured at the end of each treatment phase. Results: Compared with placebo, spironolactone reduced systolic BP by 15.6 ± 46.1 mmHg (P = 0.005, 95% CI 2.7-28.5 mmHg), PIIINP by 0.6 ± 0.3 μg l-1 (P = 0.04, 95% CI 0.02-1.1 μg l-1) and PWV by 0.6 ± 0.2 m s-1 (P = 0.008, 95% CI 0.18-1.02 m s-1). Conclusions: Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabetic patients with hypertension.

Original languageEnglish
Pages (from-to)520-523
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Volume59
Issue number5
DOIs
Publication statusPublished - 1 May 2005

Keywords

  • Diabetes
  • Hypertension
  • Spironolactone

Fingerprint

Dive into the research topics of 'Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients'. Together they form a unique fingerprint.

Cite this